Preclinical evidence

2020
Oroxylum indicum extract prevents chemotherapy‐induced cognitive impairment in mice

A study evaluated the ability of Sabroxy® to protect against chemotherapy-induced cognitive impairment in C57BL/6J mice. Neuronal oxidative stress and mitochondrial dysfunction were induced in mice by using doxorubicin (2mg/kg) and cyclophosphamide (50mg/kg) once a week for 4 weeks. The test group received powdered food mixed with Sabroxy (250mg/kg) daily for 4 weeks. After the treatment period, the mice were assessed for cognitive function using novel object recognition, Y‐maze, and Morris water maze analyses. The supplementation resulted in the prevention of chemotherapy impaired performance in the memory assessment tests. The supplementation also protected the mice against chemotherapy-induced oxidative stress and mitochondrial dysfunction in the cortex and rest of the brain. The research study concludes that Sabroxy may be offered as an adjuvant therapeutic strategy to treat chemotherapy-induced cognitive impairment.

Sabroxy significantly increased the novel object recognition (n=10, *p<0.05, as compared to the chemotherapeutics)

Sabroxy significantly increased the time spent in the novel arm in the
chemotherapeutic treated mice (n=10, *ap<0.05, as compared to the chemotherapeutics)

Sabroxy significantly increased the time spent in the platform quadrant
in the chemotherapeutic treated mice (water maze test) (n=10, ap<0.05, as compared to the chemotherapeutics)

Pondugula, Satyanarayana R et al., Oroxylum indicum extract prevents chemotherapy‐induced cognitive impairment in mice. The FASEB Journal. 2020. 34(1): 1-1.

2007
The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice

Oroxylin A was evaluated for its ability to ameliorate the scopolamine-induced memory impairment in mice model. The study employed the passive avoidance test, the Y-maze test, and the Morris water maze test as the methods to assess the memory. The mice were subjected to drug-induced amnesia by administering scopolamine (1mg/kg) or diazepam (1mg/kg). Supplementation of oroxylin A (5mg/kg) reversed the chemical-induced cognitive impairments in mice. The supplementation also improved escape latencies in training trials and increased swimming times and distances within the target zone of the Morris water maze. The study concludes that the cognitive improvement effect of oroxylin A may be mediated through its interaction with Gama amino butyric acid receptors and thus may find its implication in preparations aiming for cognitive improvement.

Kim DH, Jeon SJ, Son KH et al., The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem. 2007;87(4):536-546.